Cargando…

Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes

IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have demonstrated many cardiovascular and kidney function benefits for patients with type 2 diabetes (T2D). However, the results of SGLT-2i use in primary prevention of atrial fibrillation (AF) were inconsistent in clinical trials, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuo, Min, D’Andrea, Elvira, Paik, Julie M., Wexler, Deborah J., Everett, Brendan M., Glynn, Robert J., Kim, Seoyoung C., Patorno, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554705/ https://www.ncbi.nlm.nih.gov/pubmed/36219443 http://dx.doi.org/10.1001/jamanetworkopen.2022.35995

Ejemplares similares

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2021)

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels
por: D’Andrea, Elvira, et al.
Publicado: (2023)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitor
por: Chan, Yi-Hsin, et al.
Publicado: (2021)

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
por: Karamichalakis, Nikolaos, et al.
Publicado: (2022)

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
por: Chang, Sheng‐Nan, et al.
Publicado: (2023)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Ling, Ann Wan-Chin, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
por: Xie, Yan, et al.
Publicado: (2021)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
por: Choi, Y, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
por: Peng, Xiaodong, et al.
Publicado: (2020)

Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
por: Wei, Jie, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes
por: Ko, Hwa Yeon, et al.
Publicado: (2023)

Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice
por: Piątkowska-Chmiel, Iwona, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
por: Ouyang, Xiaolan, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by AKI
por: Aklilu, Abinet M., et al.
Publicado: (2023)

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study
por: Fralick, Michael, et al.
Publicado: (2020)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
por: Ring, Arne, et al.
Publicado: (2013)

Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
por: Connelly, Kim A., et al.
Publicado: (2018)

The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors
por: Chan, Yi-Hsin, et al.
Publicado: (2021)

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2018)

Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study
por: Chen, Tien-Hsing, et al.
Publicado: (2020)

Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
por: Bhattarai, Mukul, et al.
Publicado: (2022)

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
por: Sayour, Alex Ali, et al.
Publicado: (2020)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1om2e33drhvf714vduio975bha